Formulation technology to repurpose drugs for inhalation delivery

Drug Discovery Today: Therapeutic Strategies

Volumn 8, Issue 3-4, 2011, Pages 123-130

  Cipolla, David C ^a   Gonda, Igor ^a  

^a ARADIGM CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; AMIKACIN; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ARIKACE; ATROPINE; AZTREONAM LYSINE; BECLOMETASONE DIPROPIONATE; BRONCHODILATING AGENT; BUDESONIDE; CIPROFLOXACIN; CISPLATIN; CORTICOSTEROID; CROMOGLYCATE DISODIUM; CYCLOSPORIN; EPHEDRINE; FLUNISOLIDE; HYDROCORTISONE; ILOPROST; IPRATROPIUM BROMIDE; LIPOQUIN; MORPHINE; PREDNISOLONE; PROSTACYCLIN DERIVATIVE; PULMAQUIN; RECOMBINANT HUMAN INSULIN; SALBUTAMOL; SCOPOLAMINE; TERBUTALINE; TIOTROPIUM BROMIDE; TOBRAMYCIN; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; UNIPROST;

AEROSOL; ANTICHOLINERGIC EFFECT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; BLOOD PRESSURE; BRONCHIOLITIS OBLITERANS; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTINUOUS INFUSION; CYSTIC FIBROSIS; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG COST; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MARKETING; DRUG POTENCY; DRUG RELEASE; DRUG SAFETY; DRUG SOLUBILITY; DRUG TOLERABILITY; EVAPORATION; EXERCISE; HEADACHE; HUMAN; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; INHALATIONAL DRUG ADMINISTRATION; JAW PAIN; LARYNX; LIPOPHILICITY; LUNG CANCER; LUNG CIRCULATION; LUNG GRAFT REJECTION; LUNG VENTILATION PERFUSION RATIO; METERED DOSE INHALER; MOLECULAR WEIGHT; MORBIDITY; MORTALITY; NAUSEA; NEBULIZATION; NEBULIZER; OROPHARYNX; PARENTERAL DRUG ADMINISTRATION; PSEUDOMONAS AERUGINOSA; PULMONARY HYPERTENSION; RESPIRATORY SYSTEM; SIDE EFFECT; SMOKING; STEROID THERAPY; SURVIVAL; VASCULAR RESISTANCE; VOMITING;

EID: 84862212854     PISSN: None     EISSN: 17406773     Source Type: Journal    
DOI: 10.1016/j.ddstr.2011.07.001     Document Type: Review

References (40)

1. Garnier, J.P. (2008) Rebuilding the R&D engine in big Pharma. Harv. Bus. Rev. 86, 69-76
2. Munos, B. (2009) Lessons from 60 years of pharmaceutical innovation. Nat. Rev. 8, 959-968
3. Adams, C.P. and Branter, V.V. (2006) Estimating the cost of new drug development: is it really $802 million dollars? Health Aff. (Millwood) 25, 420-428 (Pubitemid 43529550)
4. Gross, N.J. (1993) Anticholinergic agents. In Bronchial Asthma, Mechanisms and Therapeutics (3rd edn) (Weiss, E.B. and Stein, M., eds), pp. 876-883, Little, Brown and Company
5. Jenne, J.W. and Tashkin, D.P. (1993) Beta-adrenergic agonists. In Bronchial Asthma, Mechanisms and Therapeutics (3rd edn) (Weiss, E.B. and Stein, M., eds), pp. 700-748, Little, Brown and Company
6. Toogood, J.H. et al. (1993) Aerosol corticosteroids. In Bronchial Asthma, Mechanisms and Therapeutics (3rd edn) (Weiss, E.B. and Stein, M., eds), pp. 818-841, Little, Brown and Company
7. Cipolla, D. et al. (2011) Liposomes, niosomes and proniosomes -a critical update of their (commercial) development as inhaled products. In Respiratory Drug Delivery Europe (Dalby, R.N., Byron, P.R., Peart, J., Suman, J.D., Farr, S.J., Young, P.M., eds), pp. 41-54, Davis Healthcare Int'l Publishing
8. Becker, K.A. et al. (2010) The role of sphingolipids and ceramide in pulmonary inflammation in cystic fibrosis. Open Respir. Med. J. 30, 39-47
9. Gonda, I. (2000) The ascent of pulmonary drug delivery. J. Pharm. Sci. 89, 940-945
10. Patton, J. et al. (2004) The lungs as a portal of entry for systemic drug delivery. Proc. Am. Thorac. Soc. 1, 338-344
11. Weers, J.G. et al. (2010) Pulmonary formulations: what remains to be done? J. Aerosol Med. Pulm. Drug Deliv. 23 (S2), S5-S23
12. Cipolla, D. and Johansson, E. (2008) AERx pulmonary drug delivery systems. In Modified Release Drug Delivery Technology (2nd edn) (Rathbone, M.J., Hadgraft, J., Roberts, M.S., Lane, M.E., eds), pp. 563-571
13. Gonda, I. (1997) Deoxyribonuclease inhalation. In Inhalation Delivery of Therapeutic Peptides and Proteins (Adjei, A.L. and Gupta, P.K., eds), pp. 355-365, Marcel Dekker
14. Balwani, G. et al. (2002) Evaluation of the AERx System for the Pulmonary Delivery of Recombinant Human Interferon Alfa-2b to Healthy Subjects. CRS
15. Angelo, R. et al. (2009) Technosphere insulin: defining the role of technosphere particles at thecellular level. J.Diabetes Sci. Technol. 3, 545-554
16. Gessler, T. et al. (2008) Inhaled prostanoids in the therapy of pulmonary hypertension. J. Aerosol Med. 21, 1-12
17. Iacono, A.T. et al. (2006) A randomized trial of inhaled cyclosporine in lung-transplant recipients. N. Engl. J. Med. 354, 141-150 (Pubitemid 43076711)
18. Behr, J. et al. (2009) Lung deposition of a liposomal cyclosporine A solution in patients after lung transplantation. J. Aerosol Med. Pulm. Drug Deliv. 22, 121-129
19. Gagnadoux, F. et al. (2008) Aerosolized chemotherapy. J. Aerosol Med. Pulm. Drug Deliv. 21, 61-69
20. Wittgen, B.P.H. et al. (2007) Phase 1 study of aerosolized SLIT cisplatin in the treatment of patients with carcinoma of the lung. Clin. Cancer Res. 13, 2414-2421 (Pubitemid 46698592)
21. Edwards, D. et al. (1997) Large porous particles for pulmonary drug delivery. Science 276, 1868-1871 (Pubitemid 27443665)
22. Farr, S. et al. (2000) Pulmonary insulin administration using the AERx system: physiological and physicochemical factors influencing insulin effectiveness in healthy fasting subjects. Diabetes Technol. Ther. 2, 185-197 (Pubitemid 30412817)
23. Noymer, P. et al. Pulmonary delivery of therapeutic compounds for treating central nervous system disorders. Ther. Deliv. (in press)
24. Patton, J. et al. (1998) Pulmonary absorption and metabolism of peptides and proteins. In Respiratory Drug Delivery VI (Dalby, R.N., Byron, P.R., Farr, S.J., eds), pp. 17-24, Interpharm Press
25. Siekmeier, R. and Scheuch, G. (2008) Systemic treatment by inhalation of macromolecules -principles, problems and examples. J. Phys. Pharm. 59 (Suppl. 6), 53-79
26. Wolff, R. (1998) Safety of inhaled proteins for therapeutic use. J. Aerosol Med. 11, 197-219 (Pubitemid 28563960)
27. Walvoord, E. et al. (2009) Inhaled growth hormone (GH) compared with subcutaneous GH in children with GH deficiency: pharmacokinetics, pharmacodynamics, and safety. J. Clin. Endocrinol. Metab. 94, 2052-2059
28. Aurora, S.K. et al. (2011) MAP0004, orally inhaled DHE: a randomized, controlled study in acute treatment of migraine. Headache 51, 507-517
29. Lesem, M.D. et al. (2011) Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine. Br. J. Psychiatry 198, 51-58
30. Gonda, I. et al. (2009) Smoking cessation approach via deep lung delivery of 'clean' nicotine. In RDD Europe 2009 Respiratory Drug Delivery (Dalby, R.N., Byron, P.R., Peart, J., Suman, J.D., Young, P.M., eds), pp. 57-61, Davis Healthcare Int'l Publications
31. Finlay, W.H. (2001) The Mechanics of Inhaled Pharmaceutical Aerosols. Academic Press
32. Cipolla, D. et al. (2010) Personalized medicine: development of inhalation systems tailored to the individual. Ther. Deliv. 1, 667-682
33. Shrewsbury, S.B. et al. (2009) Pharmacokinetics of a novel submicron budesonide dispersion for nebulized delivery in asthma. Int. J. Pharm. 365, 12-17
34. Shrewsbury, S.B. et al. (2008) Breath-synchronized plume-control inhaler for pulmonary delivery of fluticasone propionate. Int. J. Pharm. 356, 137-143
35. Chan, H.K. (2006) Dry powder aerosol delivery systems: current and future research directions. J. Aerosol Med. 19, 21-35
36. Timmons, R.D. et al. (2008) Feasibility study of nicotine aerosol generation using the staccato system. In Respiratory Drug Delivery Europe (Dalby, R.N., Byron, P.R., Peart, J., Suman, J.D., Farr, S.J., Young, P.M., eds), pp. 359-363, Davis Healthcare Int'l Publishing
37. Hussain, A. et al. (2003) Absorption enhancers in pulmonary protein delivery. J. Control. Rel. 94, 15-24
38. Bitonti, A. et al. (2004) Pulmonary delivery of an erythropoeitin Fc fusion protein in non-human primates through an immunoglobulin transport pathway. PNAS 101, 9763-9768 (Pubitemid 38869310)
39. Cipolla, D. et al. (2001) Delivery of biologics to the lung. In New Drugs for Asthma, Allergy and COPD, (30) (Hansel, T.T. and Barnes, P.J., eds) pp. 20-23, S. Karger AG (Pubitemid 33253188)
40. Hubbard, R.C. and Crystal, R.G. (1990) Strategies for aerosol therapy of alpha1-antitrypsin deficiency by the aerosol route. Lung Suppl. 168, 565-578 (Pubitemid 20217698)